Meeting
2011 ASCO Annual Meeting
Observation prior to systemic therapy in patients with metastatic renal cell carcinoma in the kinase inhibitor era.
Authors
R. A. Fisher
The Royal Marsden NHS Foundation Trust, London, United Kingdom
R. A. Fisher , A. Pender , K. Thillai , S. Chowdhury , L. M. Pickering , S. St. Rose , M. E. Gore , J. M. G. Larkin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4630)
Abstract #
4630
Poster Bd #
8F
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Monitoring efficacy of neoadjuvant sunitinib in metastatic renal cell carcinoma using a personalized and tumor informed ctDNA assay.
First Author: Christine B. Peterson
Poster
2023 ASCO Genitourinary Cancers Symposium
Outcomes Database to Prospectively Assess the Changing Therapy Landscape in Renal Cell Carcinoma (ODYSSEY RCC).
First Author: Michael Roger Harrison
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of systemic therapy (ST) on deferred cytoreductive nephrectomy (CN) perioperative outcomes: A National Surgical Quality Improvement Program (NSQIP) analysis.
First Author: Shawn Dason
Poster
2022 ASCO Genitourinary Cancers Symposium
A VA Federal Supply Schedule (VAFSS)–based cost-effectiveness analysis of immunotherapy-tyrosine kinase inhibitor (IO-TKI) regimens and sunitinib in the treatment of metastatic renal cell carcinoma (mRCC).
First Author: Manish Kohli